Jonathan Chang Analyst Performance

Senior Research Analyst at Leerink Partners

Jonathan Chang is a stock analyst at Leerink Partners in the medical sector, covering 9 publicly traded companies. Over the past year, Jonathan Chang has issued 4 stock ratings, including buy and hold recommendations. While full access to Jonathan Chang's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jonathan Chang's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 13 Last 7 Years
Buy Recommendations: 83.33% 10 Buy Ratings
Companies Covered: 9 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	83.3%	10 ratings
Hold	16.7%	2 ratings
Sell	0.0%	0 ratings

Out of 12 total stock ratings issued by Jonathan Chang at Leerink Partners, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Best & Worst Calls

Best Call
0000.0%
ZLAB
Jun 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
ADAP
Mar 2018
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	9 companies

Jonathan Chang, an analyst at Leerink Partners, currently covers 9 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 9 companies	100.0%

Jonathan Chang of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 5 companies	55.6%
MED - DRUGS 2 companies	22.2%
BIOTECHNOLOGY 1 company	11.1%
PHARMACEUTICAL PREPARATIONS 1 company	11.1%

About Jonathan Chang

Jonathan Chang, Ph.D., CFA is a Senior Research Analyst at Leerink Partners covering Emerging Oncology. He has been an important contributor to the Firm’s biotechnology research product and insights. Jonathan joined the Firm in 2013 as an Associate supporting the Firm’s senior oncology biotechnology research team and in 2016, he assumed research coverage of several important emerging biotechnology companies. In 2018, he was named a Rising Star in Institutional Investor’s 2018 All-America Research Team for Biotechnology/Mid- & Small-Cap. He earned a Ph.D. in Pharmacology from Cornell University, an M.A. in Biotechnology from Columbia University, and an Honors B.Sc. in Genes, Genetics, and Biotechnology from the University of Toronto. Dr. Chang is a CFA charter holder.

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
NBTX Nanobiotix	9/18/2025	Set Price Target	$11.51	$14.00
REPL Replimune Group	7/22/2025	Reiterated Rating	$2.96	$3.00	Market Perform
ZLAB Zai Lab	6/30/2025	Set Price Target	$34.79	$75.00	Outperform
GMAB Genmab A/S	2/13/2025	Upgrade	$19.69	$27.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.